Ready to contact us for a consultation about your condition and our medical services? The staff of our Global Patient Services is ready to help. Please select the appropriate button to get started.

Therapy-Resistant Basal Cell Carcinoma Patients React Positively to New Treatment

Immunotherapy found to be effective for the treatment of basal cell carcinoma skin cancer

Basal cell carcinoma (BCC) is a type of cancer that most often develops on areas of skin exposed to the sun, such as the face, and is the most common form of skin cancer. Traditionally, BCC is treated with surgery to remove the malignant tissue. When the type of the tumor does not allow for surgery, doctors often employ biological drugs. However, the latter can cause severe side effects.

Highly effective, and with fewer side effects compared to other BCC immunotherapy drugs, Cemiplimab offers new hope for patients. A PD-1 inhibitor, Cemiplimab blocks the activity of certain checkpoint proteins that tend to be present on the surface of cells and signal immune cells not to attack.

According to a recent study by Sheba Medical Center, Cemiplimab is highly effective in treating BCC, as the tumor shrunk significantly in 30 percent of participants, while 60 percent experienced some reduction in size or a halt in development. These patients either did not react to standard biological treatments or experienced severe side effects.

Sheba's Legacy of Hope: Alexandra's Remarkable Road to Wellness
Last month, a celebratory atmosphere filled the halls of the Edmond and Lily Safra Children’s Hospital at Sheba. The occasion marked a significant milestone in…
Read More
Kerry's Fight Against Skin Cancer at Sheba
Looking back at 2020, 55-year-old Kerry Louise Matthews was in love with her life. Despite the pandemic, the UK native had just started on a…
Read More
Sheba Ranked Among the Top 10 Hospitals in the World by Newsweek
We are pleased to announce that for the sixth consecutive year, Sheba has been recognized as one of the best hospitals in the world by…
Read More